Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2M93X)

Drug Name

Efgartigimod alfa Drug Info

Synonyms

Efgartigimod

Indication

Disease Entry	ICD 11	Status	REF
Myasthenia gravis	8C6Y	Approved	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Neonatal Fc receptor (FCGRT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ARGX-113	DM180DM	Myasthenia gravis	8C6Y	Phase 3	[2]
Batoclimab	DMYPMR8	Myasthenia gravis	8C6Y	Phase 3	[3]
Nipocalimab?	DM0DYAX	Chronic inflammatory demyelinating polyneuropathy	8C01.3	Phase 3	[4]
SYN-1327	DMFNR75	Discovery agent	N.A.	Investigative	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	FDA Approved Drug Products from FDA Official Website. 2021. Application Number: 761195.
2	Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019 Jun 4;92(23):e2661-e2673.
3	Batoclimab as an add-on therapy in neuromyelitis optica spectrum disorder patients with acute attacks. Eur J Neurol. 2023 Jan;30(1):195-203.
4	New Therapies for the Treatment of Warm Autoimmune Hemolytic Anemia. Transfus Med Rev. 2022 Oct;36(4):175-180.
5	Structure-activity relationships of a peptide inhibitor of the human FcRn:human IgG interaction. Bioorg Med Chem. 2008 Jun 15;16(12):6394-405.